Cargando…
Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
BACKGROUND: In the European Union (EU) and United States (US), specific regulations have been released to provide incentives to develop and sell orphan medicinal products. We analysed the status of orphan drugs designated that not yet received a marketing authorisation or already marketed for patien...
Autores principales: | Giannuzzi, Viviana, Conte, Rosa, Landi, Annalisa, Ottomano, Serena Antonella, Bonifazi, Donato, Baiardi, Paola, Bonifazi, Fedele, Ceci, Adriana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376695/ https://www.ncbi.nlm.nih.gov/pubmed/28372595 http://dx.doi.org/10.1186/s13023-017-0617-1 |
Ejemplares similares
-
Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs
por: Giannuzzi, Viviana, et al.
Publicado: (2017) -
Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed
por: Ceci, Adriana, et al.
Publicado: (2023) -
Paediatric Medicines in Europe: The Paediatric Regulation—Is It Time for Reform?
por: Toma, Maddalena, et al.
Publicado: (2021) -
PedCRIN tool for the biosamples management in pediatric clinical trials
por: Giannuzzi, Viviana, et al.
Publicado: (2023) -
Ethical and procedural issues for applying researcher-driven multi-national paediatric clinical trials in and outside the European Union: the challenging experience of the DEEP project
por: Giannuzzi, Viviana, et al.
Publicado: (2021)